XenoTherapeutics Corporation is a clinical-stage biotechnology company with a platform focused on the immunogenomic reprogramming of foreign cells for the purpose of transplanting organs and tissues from other species into human patients.
In 2019, XenoTherapeutics performed the first FDA-cleared non-human organ transplant in the United States at the Massachusetts General Hospital.
To stave off preventable mortality and to convert the hope of second chances into reality.
We exist to radically solve the unforgiving need for organ and tissue transplantation
—for all humankind.
As a virtual biotechnology company (VIBCO), our corporate structure is streamlined and decentralized, which permits the recruitment and utilization of collaborators, vendors, and access to subject matter experts who previously would have been unable to form highly specialized and domain-focused teams. These partners are not “our arms and our legs,” but they are our thinking partners. This results in an expertise reach that was previously unattainable; the use of contracted specialists for specific projects replaces former reliance on generalists, limited by “in-house-only” capabilities. This dynamic method of precise outsourcing dramatically reduces expenses and minimizes costly operational inefficiencies where full-time employees in the static, traditional model often are sub-optimally engaged. This is why our team can combine into a force that looks much bigger, operates much faster, and achieves more with less by comparison to our peers.
Our business model harnesses the vision, creativity, and mission-driven passion of the non-profit sector (XenoTherapeutics Foundation) with the resources, pragmatism, and expertise of the for-profit corporation (XenoTherapeutics Corporation) to support the rapid development of tangible therapeutic solutions to address a critical, growing unmet medical need.
XenoTherapeutics Corporation exclusively sub-licenses intellectual property from XenoTherapeutics Foundation for commercialization purposes. XenoTherapeutics Corporation can raise money through traditional channels open to for-profit entities (stock sales, loans, etc). It then provides XenoTherapeutics Foundation with a steady source of funding via a sponsored research agreement for continued research efforts and further development since relying on an unpredictable stream of charitable contributions is enormously disruptive to the process of funding essential research and building quality teams. Both entities continually collaborate on intellectual property strategy.
The non-profit/for-profit joint venture model de-risks and optimizes therapeutic candidates by leveraging favorable regulatory indications and decreasing time to market.